PE20061353A1 - SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORS - Google Patents
SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORSInfo
- Publication number
- PE20061353A1 PE20061353A1 PE2006000347A PE2006000347A PE20061353A1 PE 20061353 A1 PE20061353 A1 PE 20061353A1 PE 2006000347 A PE2006000347 A PE 2006000347A PE 2006000347 A PE2006000347 A PE 2006000347A PE 20061353 A1 PE20061353 A1 PE 20061353A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- optionally substituted
- compounds
- sulfonamide
- cyclopentil
- Prior art date
Links
- 239000012190 activator Substances 0.000 title abstract 2
- -1 CYANE Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 229940080818 propionamide Drugs 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS SULFONAMIDA-TIAZOLOPIRIDINA DE FORMULA (I), EN DONDE R1 ES H, HALOGENO, CIANO, NITRO, ENTRE OTROS; R2 ES CICLOALQUILO(C3-C6) O HETEROCICLILO(C3-C6); R3 ES H, HALOGENO, CIANO, ALQUILO(C1-C7), ENTRE OTROS; R4 ES H, ALQUILO(C1-C20) OPCIONALMENTE SUSTITUIDO CON HALOGENO, HIDROXI, SULFONILO, ENTRE OTROS, O CICLOALQUILO(C3-C12); R5 ES -(CR6R7)m-W-R8 DONDE R6 Y R7 SON H, ALQUILO(C1-C20) OPCIONALMENTE SUSTITUIDO, CICLOALQUILO(C3-C12), ENTRE OTROS; m ES DE 0 A 5; W ES NR9 DONDE R9 ES H, HETEROCICLILO TAL COMO PIRROLILO, BENZOTIAZOLILO, FENANTRIDINILO, ENTRE OTROS, ALQUILO(C1-C20) OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; R8 ES H, ALQUILO(C1-C7) OPCIONALMENTE SUSTITUIDO, ARILO(C6-C12), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-CICLOPENTIL-2-(4-CICLOPROPILSULFAMOIL-FENIL)-N-(5-METOXI-TIAZOLO[5,4-b]PIRIDIN-2-IL)PROPIONAMIDA, 3-CICLOPENTIL-2-[4-(2-METOXI-ETILSULFAMOIL)-FENIL]-N-(5-METOXI-TIAZOLO[5,4-b]PIRIDIN-2-IL)-PROPIONAMIDA, 3-CICLOPENTIL-N-(5-METOXI-TIAZOLO[5,4-b]PIRIDIN-2-IL)-2-(4-FENILSULFAMOIL-FENIL)PROPIONAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ACTIVADORES DE GLUCOCINASA SIENDO UTILES EN EL TRATAMIENTO DE TOLERANCIA DANADA A GLUCOSA, DIABETES TIPO 2, OBESIDADREFERS TO SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS OF FORMULA (I), WHERE R1 IS H, HALOGEN, CYANE, NITRO, AMONG OTHERS; R2 IS CYCLOALKYL (C3-C6) OR HETEROCYCLYL (C3-C6); R3 IS H, HALOGEN, CYANE, ALKYL (C1-C7), AMONG OTHERS; R4 IS H, ALKYL (C1-C20) OPTIONALLY SUBSTITUTED WITH HALOGEN, HYDROXY, SULFONIL, AMONG OTHERS, OR CYCLOALKYL (C3-C12); R5 IS - (CR6R7) m-W-R8 WHERE R6 AND R7 ARE H, ALKYL (C1-C20) OPTIONALLY SUBSTITUTED, CYCLOALKYL (C3-C12), AMONG OTHERS; m IS 0 TO 5; W IS NR9 WHERE R9 IS H, HETEROCYCLYL SUCH AS PYRROLYL, BENZOTHIAZOLYL, PHENANTHRIDINYL, AMONG OTHERS, ALKYL (C1-C20) OPTIONALLY SUBSTITUTED, AMONG OTHERS; R8 IS H, ALKYL (C1-C7) OPTIONALLY SUBSTITUTED, ARYL (C6-C12), AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: 3-CYCLOPENTIL-2- (4-CYCLOPROPYLSULFAMOYL-PHENYL) -N- (5-METOXY-THIAZOLO [5,4-b] PYRIDIN-2-IL) PROPIONAMIDE, 3-CYCLOPENTIL-2- [4- (2-METHOXY-ETHYLSULFAMOIL) -PHENYL] -N- (5-METOXY-THIAZOLO [5,4-b] PYRIDIN-2-IL) -PROPIONAMIDE, 3-CYCLOPENTIL-N- (5-METOXY-THIAZOLO [5, 4-b] PYRIDIN-2-IL) -2- (4-PHENYLSULFAMOIL-PHENYL) PROPIONAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE GLUCOCINASE ACTIVATORS, BEING USEFUL IN THE TREATMENT OF DAMAGED GLUCOSE TOLERANCE, TYPE 2 DIABETES, OBESITY
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55918404P | 2004-04-02 | 2004-04-02 | |
| PCT/EP2005/003456 WO2005095418A1 (en) | 2004-04-02 | 2005-04-01 | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061353A1 true PE20061353A1 (en) | 2006-12-29 |
Family
ID=34963913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000347A PE20061353A1 (en) | 2004-04-02 | 2006-03-29 | SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORS |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7750020B2 (en) |
| EP (1) | EP1735322B1 (en) |
| JP (1) | JP4700684B2 (en) |
| KR (1) | KR100830007B1 (en) |
| CN (1) | CN1960995B (en) |
| AR (1) | AR050913A1 (en) |
| AT (1) | ATE524479T1 (en) |
| AU (1) | AU2005229416B2 (en) |
| BR (1) | BRPI0509573A (en) |
| CA (1) | CA2560689C (en) |
| EC (1) | ECSP066894A (en) |
| IL (1) | IL178151A0 (en) |
| MA (1) | MA28528B1 (en) |
| NO (1) | NO20064929L (en) |
| PE (1) | PE20061353A1 (en) |
| PT (1) | PT1735322E (en) |
| RU (1) | RU2412192C2 (en) |
| TN (1) | TNSN06315A1 (en) |
| WO (1) | WO2005095418A1 (en) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102299D0 (en) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (en) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| CA2498089A1 (en) | 2002-10-03 | 2004-06-17 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| CN101098876A (en) * | 2004-04-02 | 2008-01-02 | 诺瓦提斯公司 | Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| NZ575512A (en) | 2005-07-09 | 2009-11-27 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes |
| GT200600429A (en) * | 2005-09-30 | 2007-04-30 | ORGANIC COMPOUNDS | |
| GT200600428A (en) * | 2005-09-30 | 2007-05-21 | ORGANIC COMPOUNDS | |
| CN101316837A (en) * | 2005-11-01 | 2008-12-03 | 詹森药业有限公司 | Substituted pyrrolones as allosteric modulators of glucokinase |
| US7531671B2 (en) * | 2005-11-01 | 2009-05-12 | Janssen Pharmaceutica N.V. | Dihydroisoindolones as allosteric modulators of glucokinase |
| CA2627910A1 (en) * | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase |
| CN101316836A (en) | 2005-11-01 | 2008-12-03 | 詹森药业有限公司 | Substituted dihydroisoindolones as allosteric modulators of glucokinase |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118854A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| PE20110235A1 (en) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE |
| AU2007278261A1 (en) | 2006-07-24 | 2008-01-31 | F. Hoffmann-La Roche Ag | Pyrazoles as glucokinase activators |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| CN101687800B (en) * | 2007-03-07 | 2012-03-21 | 杏林制药株式会社 | glucokinase activating substance |
| WO2008119734A2 (en) * | 2007-03-29 | 2008-10-09 | Novartis Ag | Process for the manufacture of organic compounds |
| US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| AU2008310519B2 (en) * | 2007-10-08 | 2013-05-02 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| CN101417987B (en) * | 2007-10-24 | 2011-07-13 | 山东轩竹医药科技有限公司 | DPP-IV inhibitor with sulfonamide formyl piperazine structure |
| RU2010134411A (en) | 2008-01-18 | 2012-02-27 | Астеллас Фарма Инк. (Jp) | Phenylacetamide Derivative |
| US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
| US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| RU2565070C2 (en) * | 2008-04-28 | 2015-10-20 | Киорин Фармасьютикал Ко., Лтд. | Cyclopentylacrylamide derivative |
| US8563730B2 (en) | 2008-05-16 | 2013-10-22 | Takeda San Diego, Inc. | Pyrazole and fused pyrazole glucokinase activators |
| AU2009290474A1 (en) * | 2008-09-11 | 2010-03-18 | Pfizer Inc. | Heteroaryls amide derivatives and their use as glucokinase activators |
| CA2754681C (en) | 2009-03-11 | 2014-01-07 | Pfizer Inc. | Benzofuranyl derivatives used as glucokinase inhibitors |
| JP6073677B2 (en) | 2009-06-12 | 2017-02-01 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Fused heterocyclic compounds and their use |
| US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2011123572A1 (en) | 2010-03-31 | 2011-10-06 | The Scripps Research Institute | Reprogramming cells |
| JP6106685B2 (en) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Inhibitors of C-JUN-N-terminal kinase (JNK) |
| WO2013173382A1 (en) * | 2012-05-15 | 2013-11-21 | Amgen Inc. | Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein |
| US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CA2927917C (en) | 2013-10-18 | 2022-08-09 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2020005807A1 (en) | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| JP7660063B2 (en) | 2018-12-28 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Inhibitors of cyclin-dependent kinase 7 and their uses |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| RU2242469C2 (en) * | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Glucokinase activating agents |
| HRP20010688B1 (en) | 1999-03-29 | 2008-10-31 | F. Hoffmann - La Roche Ag | Glucokinase activators |
| US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| CN1176915C (en) * | 2000-05-03 | 2004-11-24 | 霍夫曼-拉罗奇有限公司 | Inulin Kinase Activator of Alkynylphenyl Aromatic Heterocycle |
| BR0110492A (en) * | 2000-05-03 | 2003-04-08 | Hoffmann La Roche | A compound, a pharmaceutical composition comprising such a compound, a process for preparing a pharmaceutical composition, using a compound and a process for preparing a compound. |
| US6489485B2 (en) * | 2000-05-08 | 2002-12-03 | Hoffmann-La Roche Inc. | Para-amine substituted phenylamide glucokinase activators |
| PT1283830E (en) * | 2000-05-08 | 2008-08-18 | Hoffmann La Roche | Para-amine substituted phenylamide glucokinase activators |
| KR100548901B1 (en) * | 2000-05-08 | 2006-02-02 | 에프. 호프만-라 로슈 아게 | Substituted phenylacetamides and their use as glucokinase activators |
| MXPA03000365A (en) | 2000-07-20 | 2003-05-27 | Hoffmann La Roche | Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators. |
| US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| EP1341774B1 (en) * | 2000-12-06 | 2006-02-01 | F. Hoffmann-La Roche Ag | Fused heteroaromatic glucokinase activators |
| US6433188B1 (en) * | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| SE0102764D0 (en) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
| EP2305648A1 (en) | 2001-12-21 | 2011-04-06 | Novo Nordisk A/S | Amide derivatives useful as glucokinase activators |
| EP1496052B1 (en) * | 2002-03-26 | 2009-08-05 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| WO2003095438A1 (en) | 2002-04-26 | 2003-11-20 | F. Hoffmann-La Roche Ag | Substituted phenylacetamides and their use as glucokinase activators |
| US20070231874A1 (en) | 2002-05-16 | 2007-10-04 | Kenji Kamata | Crystal of glucokinase protein, and method for drug design using the crystal |
| CA2488642C (en) | 2002-06-27 | 2011-09-06 | Dharma Rao Polisetti | Aryl carbonyl derivatives as glucokinase activators |
| CA2498089A1 (en) | 2002-10-03 | 2004-06-17 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| PL375149A1 (en) | 2002-10-03 | 2005-11-28 | F.Hoffmann-La Roche Ag | Indole-3-carboxamides as glucokinase (gk) activators |
| PE20040801A1 (en) | 2002-12-12 | 2004-11-25 | Hoffmann La Roche | PYRAZINE AND PYRIDINE 5-SUBSTITUTED DERIVATIVES AS GLUCOKINASE ACTIVATORS |
| ES2362656T3 (en) | 2003-01-06 | 2011-07-11 | Eli Lilly And Company | ARILCICLOPROPILACETAMIDES REPLACED AS GLUCOQUINASE ACTIVATORS. |
| WO2004063194A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Heteroaryl compounds |
| WO2004072066A1 (en) | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| PL378117A1 (en) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tri(cyclo) substituted amide compounds |
| PE20050194A1 (en) | 2003-02-13 | 2005-04-23 | Banyu Pharma Co Ltd | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS |
| AU2004215514B2 (en) | 2003-02-26 | 2010-03-04 | Msd K.K. | Heteroarylcarbamoylbenzene derivative |
| CN101098876A (en) * | 2004-04-02 | 2008-01-02 | 诺瓦提斯公司 | Thiazolopyridine derivates, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions |
| JP2007533722A (en) | 2004-04-21 | 2007-11-22 | プロシディオン・リミテッド | Tri (cyclo) substituted amide compounds |
| CA2576407A1 (en) | 2004-08-12 | 2006-02-16 | Prosidion Limited | Substituted phenylacetamides and their use as glucokinase activators |
| MX2007006420A (en) | 2004-12-03 | 2007-07-19 | Novo Nordisk As | Heteroaromatic glucokinase activators. |
| GT200600429A (en) | 2005-09-30 | 2007-04-30 | ORGANIC COMPOUNDS | |
| GT200600428A (en) * | 2005-09-30 | 2007-05-21 | ORGANIC COMPOUNDS |
-
2005
- 2005-04-01 JP JP2007505512A patent/JP4700684B2/en not_active Expired - Fee Related
- 2005-04-01 WO PCT/EP2005/003456 patent/WO2005095418A1/en not_active Ceased
- 2005-04-01 KR KR1020067020441A patent/KR100830007B1/en not_active Expired - Fee Related
- 2005-04-01 CN CN2005800178910A patent/CN1960995B/en not_active Expired - Fee Related
- 2005-04-01 RU RU2006138433/04A patent/RU2412192C2/en not_active IP Right Cessation
- 2005-04-01 PT PT05731007T patent/PT1735322E/en unknown
- 2005-04-01 AT AT05731007T patent/ATE524479T1/en not_active IP Right Cessation
- 2005-04-01 EP EP05731007A patent/EP1735322B1/en not_active Expired - Lifetime
- 2005-04-01 US US11/547,046 patent/US7750020B2/en not_active Expired - Fee Related
- 2005-04-01 CA CA2560689A patent/CA2560689C/en not_active Expired - Fee Related
- 2005-04-01 AU AU2005229416A patent/AU2005229416B2/en not_active Ceased
- 2005-04-01 BR BRPI0509573-5A patent/BRPI0509573A/en not_active IP Right Cessation
- 2005-08-09 AR ARP050103320A patent/AR050913A1/en not_active Application Discontinuation
-
2006
- 2006-03-29 PE PE2006000347A patent/PE20061353A1/en not_active Application Discontinuation
- 2006-09-18 IL IL178151A patent/IL178151A0/en unknown
- 2006-09-29 EC EC2006006894A patent/ECSP066894A/en unknown
- 2006-09-29 TN TNP2006000315A patent/TNSN06315A1/en unknown
- 2006-10-11 MA MA29381A patent/MA28528B1/en unknown
- 2006-10-27 NO NO20064929A patent/NO20064929L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2412192C2 (en) | 2011-02-20 |
| MA28528B1 (en) | 2007-04-03 |
| PT1735322E (en) | 2012-01-12 |
| US20080103167A1 (en) | 2008-05-01 |
| ECSP066894A (en) | 2006-11-24 |
| WO2005095418A1 (en) | 2005-10-13 |
| CA2560689A1 (en) | 2005-10-13 |
| JP4700684B2 (en) | 2011-06-15 |
| AU2005229416A1 (en) | 2005-10-13 |
| JP2007530632A (en) | 2007-11-01 |
| AR050913A1 (en) | 2006-12-06 |
| IL178151A0 (en) | 2006-12-31 |
| KR20060131955A (en) | 2006-12-20 |
| CN1960995B (en) | 2010-12-08 |
| BRPI0509573A (en) | 2007-09-25 |
| RU2006138433A (en) | 2008-05-10 |
| NO20064929L (en) | 2006-12-20 |
| KR100830007B1 (en) | 2008-05-15 |
| TNSN06315A1 (en) | 2007-12-03 |
| AU2005229416B2 (en) | 2009-03-26 |
| EP1735322A1 (en) | 2006-12-27 |
| CA2560689C (en) | 2011-03-01 |
| ATE524479T1 (en) | 2011-09-15 |
| EP1735322B1 (en) | 2011-09-14 |
| US7750020B2 (en) | 2010-07-06 |
| CN1960995A (en) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20061353A1 (en) | SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORS | |
| PE20060777A1 (en) | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | |
| PE20060361A1 (en) | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOTIC KINESINE | |
| PE20090952A1 (en) | RAF MODULATING PIRAZOLE COMPOUNDS | |
| PE20091734A1 (en) | 2-IMINO-3-METHYLPYRROLOPYRIMIDINONE PHENYL-SUBSTITUTED COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS AND THEIR USE | |
| PE20071322A1 (en) | DERIVATIVES OF 2-MORPHOLINOPYRIMIDINE AS INHIBITORS OF PHOSPHATIDINOINOSITOL (PI) 3-KINASE | |
| PE20060691A1 (en) | SERINAMIDES REPLACED BY BENZOYL | |
| PE20070115A1 (en) | DERIVATIVES OF [1,3,5] -TRIAZINE AS INHIBITORS OF ASPARTILE PROTEASES | |
| PE20070585A1 (en) | SULFONAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | |
| PE20120620A1 (en) | DIHYDROPIRAZOLONES SUBSTITUTED AS INHIBITORS OF HIF-PROPIL-4-HYDROXYLASES | |
| PE20121050A1 (en) | N- (1- (4- (1H-PYRAZOLE-5-IL) FTALAZIN-1-IL) PIPERIDIN-4-IL) -BENZAMIDE COMPOUNDS SUBSTITUTE AS ANTAGONISTS IN THE HEDGEHOG TRAJECTORY | |
| PE20091901A1 (en) | GLUCOKINASE ACTIVATORS | |
| PE20070218A1 (en) | AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE | |
| PE20061106A1 (en) | DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE | |
| PE20121010A1 (en) | BENZIMIDAZOLE DERIVATIVES | |
| PE20070136A1 (en) | COMPOUNDS DERIVED FROM N- (PYRIDIN-2-IL) -SULFONAMIDE AS INHIBITORS OF THE ENZYME 11-beta-HYDROXIESTEROID DEHIDROGENASE HUMAN TYPE 1 | |
| PE20091005A1 (en) | N- (2- (HETARYL) ARYL) ARYLSULFONAMIDES AND N- (2- (HETARYL) HETARYL) ARYLSULFONAMIDES | |
| PE20091466A1 (en) | DERIVATIVES OF 4,5-DIHYDRO-OXAZOLE-2-IL-AMINE | |
| NO20063470L (en) | Tetrazole compounds and their use of metabotrophic glutamate receptor antagonists | |
| PE20090601A1 (en) | PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS | |
| PE20140703A1 (en) | HETEROARYL DERIVATIVES AS MODULATORS OF NACHR ALPHA 7 | |
| PE20091376A1 (en) | DERIVATIVES OF PHENYLAMINE AS BETA-AMYLOID MODULATORS | |
| PE20071245A1 (en) | INDOL SULFONAMIDE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS (SPRMs) | |
| CO5700757A2 (en) | DERIVATIVES OF (3-OXO-3,4-DIHIDRO-QUINOXALIN-2-IL-AMINO) -BENZAMIDE AND RELATED COMPOUND, AS INHIBITORS OF GLUCOGEN PHOSPHORILASE FOR THE TREATMENT OF DIABETES AND OBESITY | |
| PE20080843A1 (en) | RENIN INHIBITORS AND METHOD FOR THEIR USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |